Actively Recruiting
FMT Capsules for rCDI
Led by Helsinki University Central Hospital · Updated on 2026-04-29
76
Participants Needed
1
Research Sites
244 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Double blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.
CONDITIONS
Official Title
FMT Capsules for rCDI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least twice recurrent Clostridioides difficile infection
- Experienced CDI-related diarrhea with 3 or more Bristol Stool Form Scale type 6-7 stools
- Other causes of diarrhea excluded based on clinical data
- Age over 18 years
- Remission of symptoms during antibiotic treatment (metronidazole, vancomycin, or fidaxomicin)
- No other antibiotic courses ongoing
- Able to sign the consent form or accept it electronically via Suomi.fi identification
You will not qualify if you...
- Pregnancy
- Continuous need for antibiotic treatment
- Previous anaphylactic reactions to any food
- Gastroparesis
- Life-threatening fulminant Clostridioides difficile infection
- Life expectancy less than 1 year
- Inability to sign a consent form for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Helsinki University Hospital
Helsinki, Uusimaa, Finland, 00290
Actively Recruiting
Research Team
P
Perttu Arkkila, Professor
CONTACT
S
Suvi Niku, PhD, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here